| Zocor |
All Financial Data in US $ (mln) |
| Word Search (Top 10 - by date) |
Merck Announces Second-Quarter 2010 Financial Results
Merck & Co
(July 30, 2010)
|
Abbott's Progress Study of Kaletra and Isentress Compared With a Standard HIV Regimen Meets The Pre-Specified Primary Efficacy Endpoint
Abbott Laboratories
(July 19, 2010)
|
MSD in South Africa and Adcock Ingram Enter Into Strategic Collaboration to Co-promote and Distribute Products in South Africa
Adcock Ingram
(June 24, 2010)
|
Mylan Receives Approval for Generic Version of Zocor® Tablets
Mylan
(June 18, 2010)
|
Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy for Growth in Emerging Markets
Merck & Co
(May 11, 2010)
|
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra® ( lopinavir / ritonavir ) for Treatment-Experienced Patients
Abbott Laboratories
(April 28, 2010)
|
Omthera Pharmaceuticals, Inc. Closes a $6.5M Series A led by Sofinnova Partners to Advance Epanova(™), a Prescription Omega 3 Therapy
Omthera Pharmaceuticals
(March 08, 2010)
|
Merck Announces Fourth-Quarter and Full-Year 2009 Financial Results
Merck & Co
(February 16, 2010)
|
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir® (ritonavir) Tablets
Abbott Laboratories
(February 11, 2010)
|
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Eli Lilly
(December 23, 2009)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
| Summary Product Name Information |
|
|
| Product Sales Summary 2007/08 |
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2007 |
2008
|
2008 |
| Zocor2 |
|
|
|
877 |
660 |
|
-25% |
|
|
Note: Shaded Cells3 |
|
|
More Product Information for EvaluatePharma® subscribersSubscribers see:
- Sales (historic and forecast to 2016 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
- Details of all events impacting the product
- Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)
|
Register to access more FREE content:
- 2009 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
|
|
|
|